Compare Cytokinetics Inc (CYTK) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs YieldMax NVDA Option Income Strategy ETF — how do they compare? Cytokinetics Inc trades at $81.96 (market cap $11.12B), while YieldMax NVDA Option Income Strategy ETF trades at $12.79. The key difference: Cytokinetics Inc is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| CYTK | NVDY | |
|---|---|---|
Market Cap | $11.12B | — |
Sector | Technology | Income / Options Overlay |
52-Week High | $87.26 | $17.96 |
52-Week Low | $33.23 | $12.03 |
Enterprise Value | $11.59B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
NVDY, the YieldMax NVDA Option Income Strategy ETF, trades at $12.43, down 2.51% today, reflecting bearish technical signals with moving averages indicating selling pressure. The fund generates weekly dividends but lacks traditional valuation metrics like P/E or P/S, as it is structured to monetize NVIDIA's volatility through options strategies. Recent news highlights its focus on income generation at the potential cost of capping NVIDIA's upside returns.
The outlook for NVDY hinges on sustained options premium income amid NVIDIA's stock volatility, offering high distribution yields but limiting capital appreciation. Key risks include underperformance versus holding NVIDIA directly, fee drag, and dependency on market conditions for options profitability. Investors seeking income may find value, but growth-oriented investors face significant opportunity cost.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
